NCT05619627View on ClinicalTrials.gov

Oral Dexmedetomidine in Pediatric MRI

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Anesthesia
Interventions
DRUG

Dexmedetomidine

Participants will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI

DRUG

General Anesthesia (control group)

Participants will receive general anesthesia for their MRI

Trial Locations (1)

64108

Children's Mercy Hospital, Kansas City

All Listed Sponsors
lead

Children's Mercy Hospital Kansas City

OTHER